A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

Trial Profile

A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms XAGastric
  • Most Recent Events

    • 12 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Jul 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 according to ClinicalTrials.gov record.
    • 11 Jul 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Jan 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top